Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH)
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death.
- Trial name
- ASCEND-PAH (NCT07713914)
- Testing
- Prostacyclin Pathway Agent, Sildenafil Dose Optimization
- Where
- Brazil
- Volunteers
- 196 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Hypertension, Mitral Regurgitation
Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients
Our main hypothesis is that inhalation of milrinone can reduce the elevated pulmonary arterial pressure due to severe mitral valve regurgitation without compromising systemic hemodynamics.
- Trial name
- NCT01621971
- Testing
- inhaled milrinone, intravenous milrinone
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Konkuk University Medical Center
Pulmonary Hypertension
Wave Intensity Analysis in the Pulmonary Artery
The mechanism governing how blood flows from the heart to the lungs depends on many factors including the pumping function of the right ventricle, properties of the arteries that carry the blood from the right ventricle to the…
- Trial name
- NCT01972009
- Testing
- Cardiac catheterisation
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance leading to shortness of breath and exercise intolerance.
- Trial name
- RESPONS (NCT01391104)
- Testing
- Sildenafil, Sugar Pill
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60…
- Trial name
- NCT04483115
- Testing
- TPN171H, Tadalafil
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01210443
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease, Hypertension, Pulmonary
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human.
- Trial name
- DHEA-HTAP (NCT00581087)
- Testing
- DHEA treatment
- Where
- 5 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)
The purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
- Trial name
- FETO (NCT03138863)
- Testing
- BALT GoldbBAL2 Detachable Balloon, Catheter System
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rodrigo Ruano
Thalassemia Major, Thalassemia Intermedia
Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
This is a multicenter observational case-control analysis lasting 12 months aimed at determining the prevalence of pulmonary hypertension (PAH) in patients with Thalassemia Major and Intermedia.
- Conditions
- Thalassemia Major, Thalassemia Intermedia, Pulmonary Arterial Hypertension
- Trial name
- PAH2010 (NCT01496963)
- Testing
- Physician standard-of-care according to ESC/ERS Guidelines
- Where
- 8 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Pulmonary Arterial Hypertension
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension
Pulmonary artery hypertension (PAH) is a rare, severe disease, characterized by a progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and premature death.
- Trial name
- NCT01520493
- Testing
- Submaximal exercises
- Where
- 2 sites in Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laval University
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Pulmonary Arterial Hypertension
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
- Trial name
- SCOBA-PH (NCT01330108)
- Testing
- ambrisentan
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Arterial Hypertension
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic…
- Trial name
- Biomarkers (NCT00566423)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Northwell Health
Pulmonary Arterial Hypertension, Right Heart Failure
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension.
- Trial name
- REHAB-PH (NCT03554291)
- Testing
- Famotidine 20 MG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension (PAH)
(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to…
- Trial name
- RightHeartIII (NCT03362047)
- Testing
- Riciguat Group, Macitentan Group
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- University of Giessen
Healthy Volunteers, Pulmonary Arterial Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
- Trial name
- NCT06649110
- Testing
- LTP
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Cardiovascular Diseases (CVD)
Pulmonary Arterial Hypertension and Associated Cardiovascular Disease Detection Using Artificial Intelligence
Cardiovascular disease (CVD) is a leading global cause of morbidity and mortality and excessive healthcare expenditures. Pulmonary hypertension (PH) represents an insidious and progressive subset of CVD affecting an estimated 1%…
- Trial name
- PULSAR (NCT07147725)
- Testing
- AI Stethoscope
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London